Mark Goldberg, M.D. has served as a member of our board of directors since June 2015. Dr. Goldberg has served as a member of the board of directors of ImmunoGen, Inc. since November 2011, a member of the board of directors of GlycoMimetics, Inc. since July 2014, a member of the board of directors of Idera Pharmaceuticals, Inc. since March 2014 and a member of the board of directors of Audentes Therapeutics, Inc. since December 2017. Dr. Goldberg served as a member of the board of directors of Synageva Biopharma Corp., or Synageva, from October 2008 until November 2011, when he stepped down to become a member of the executive management team at Synageva. Dr. Goldberg served as a member of the executive management team at Synageva until late 2014, rising to executive vice president, medical and regulatory strategy. In late 2014, Dr. Goldberg stepped down from the executive management team at Synageva and continued to be employed part-time, contributing to medical and regulatory strategy until leaving Synageva in June 2015 upon its acquisition by Alexion Pharmaceuticals, Inc. Prior to joining Synageva, Dr. Goldberg served in various management capacities of increasing responsibility at Genzyme from November 1996 to July 2011, including most recently as senior vice president, clinical development and global therapeutic head, oncology, genetic health, and as chairman of Genzyme’s early product development board. Prior to joining Genzyme, Dr. Goldberg was a full-time staff physician at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, where he still holds appointments. Dr. Goldberg is a part-time Associate Professor of Medicine at Harvard Medical School and currently serves as acting chief medical officer of CANbridge Life Sciences Ltd., a privately held biopharmaceutical company. Since 2010, Dr. Goldberg has also served as a volunteer on the board of directors of the New England Division of the American Cancer Society. Dr. Goldberg received an A.B. in biochemistry and molecular biology from Harvard University and an M.D. from Harvard Medical
What is Mark Alan Goldberg's net worth?
The estimated net worth of Mark Alan Goldberg is at least $812,792.38 as of December 24th, 2020. Mr. Goldberg owns 9,017 shares of Blueprint Medicines stock worth more than $812,792 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Goldberg may own. Learn More about Mark Alan Goldberg's net worth.
How do I contact Mark Alan Goldberg?
Has Mark Alan Goldberg been buying or selling shares of Blueprint Medicines?
Mark Alan Goldberg has not been actively trading shares of Blueprint Medicines in the last ninety days. Most recently, on Thursday, March 3rd, Mark Alan Goldberg bought 5,000 shares of Blueprint Medicines stock. The stock was acquired at an average cost of $59.98 per share, with a total value of $299,900.00. Learn More on Mark Alan Goldberg's trading history.
Who are Blueprint Medicines' active insiders?
Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (President, CEO & Director), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Philina Lee (Insider), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?
In the last twelve months, insiders at the biotechnology company sold shares 29 times. They sold a total of 329,167 shares worth more than $31,791,633.21. The most recent insider tranaction occured on December, 19th when Director Jeffrey W Albers sold 15,000 shares worth more than $1,346,550.00. Insiders at Blueprint Medicines own 4.2% of the company.
Learn More about insider trades at Blueprint Medicines. Information on this page was last updated on 12/19/2024.
